尼达尼布作为宿主导向治疗候选药物治疗结核病的疗效
该研究评估尼达尼布和吡非尼酮对药物敏感及耐药结核分枝杆菌的体外抗菌活性,并在慢性小鼠肺部感染模型中测试尼达尼布与异烟肼、利福平、吡嗪酰胺联用的疗效。尼达尼布对标准株H37Rv的MIC90为23.56-40.51 mg/L,与一线药物联用可缩短疗程并改善肺部炎症和纤维化,机制涉及通过JAK2/STAT3/Beclin1通路上调巨噬细胞自噬。
要点
- 尼达尼布对H37Rv标准株的MIC90为23.56-40.51 mg/L。
- 尼达尼布联合异烟肼、利福平和吡嗪酰胺可缩短小鼠结核疗程。
- 尼达尼布通过JAK2/STAT3/Beclin1通路上调巨噬细胞自噬清除结核分枝杆菌。
核心结论
- 尼达尼布对药物敏感和耐药结核分枝杆菌具有体外活性,并在小鼠感染中显示疗效,支持继续临床评估尼达尼布作为结核标准治疗的新型辅助疗法。
研究设计与样本
- 体外测定尼达尼布和吡非尼酮对药物敏感及耐药结核分枝杆菌的MIC和巨噬细胞内菌落形成单位计数。
- 采用慢性小鼠肺部感染模型检测尼达尼布的治疗疗效。
- 采用巨噬细胞转录组深度测序、共聚焦实验、siRNA敲低、Western blotting、定量RT-PCR和cfu实验研究尼达尼布的抗菌机制。
主要发现
- 尼达尼布对结核分枝杆菌标准株H37Rv的MIC90为23.56-40.51 mg/L。
- 结核小鼠模型研究显示,尼达尼布与异烟肼、利福平和吡嗪酰胺联合给药可缩短治疗持续时间,并改善肺部炎症和纤维化。
- 转录组测序分析显示尼达尼布可能通过上调巨噬细胞自噬消除结核分枝杆菌。
- 使用靶向ATG5的siRNA或自噬抑制剂3-甲基腺嘌呤抑制自噬几乎完全消除了尼达尼布对结核分枝杆菌的抑制。
- 尼达尼布通过JAK2/STAT3/Beclin1通路诱导自噬;敲低JAK2或Beclin1后尼达尼布不再抑制结核分枝杆菌;JAK2激活剂coumermycin A1和STAT3激动剂colivelin也逆转了该表型。
局限性
- 原文在结论中写明尼达尼布的体外活性和小鼠感染疗效warrant the continued clinical evaluation,即需继续临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The lengthy duration and high frequency of drug resistance associated with currently used antimycobacterial drug treatments have intensified the need for alternative therapies against Mycobacterium tuberculosis, the causative agent of TB. METHODS: MICs and intracellular macrophage cfu counts were tested to evaluate the antibacterial activity of nintedanib and pirfenidone against drug-susceptible and -resistant M. tuberculosis. A chronic murine model of pulmonary infection was used to assay the therapeutic efficacy of nintedanib. Macrophage transcriptome deep sequencing, a confocal assay, siRNA knockdown, Western blotting, quantitative RT-PCR and a cfu assay were used to investigate the antibacterial mechanism of nintedanib. RESULTS: The MIC90 of nintedanib against M. tuberculosis standard strain H37Rv was 23.56-40.51 mg/L. TB murine model studies showed that nintedanib, coadministered with isoniazid, rifampicin and pyrazinamide, shortened treatment duration, and ameliorated pulmonary inflammation and fibrosis. In mechanism studies, transcriptome sequencing analysis revealed that nintedanib may eliminate M. tuberculosis through up-regulating macrophage autophagy. Furthermore, inhibition of autophagy by using siRNA targeting ATG5 or the autophagy inhibitor 3-methyladenine almost completely abolished nintedanib-mediated suppression of M. tuberculosis. Nintedanib induced autophagy by the JAK2/STAT3/Beclin1 pathway. When JAK2 or Beclin1 were knocked down through siRNA, nintedanib no longer inhibited M. tuberculosis. JAK2 activator coumermycin A1 and STAT3 agonist colivelin also reversed this phenotype. CONCLUSIONS: In vitro activity of nintedanib against drug-susceptible and -resistant M. tuberculosis and efficacy in murine infections warrant the continued clinical evaluation of nintedanib as a new adjuvant therapy for standard treatment of TB.
引用
- Li X, Qi X, Wang B, et al. Efficacy of nintedanib as a host-directed therapy candidate in the treatment of tuberculosis. J Antimicrob Chemother. 2025. PMID: 39656809. doi:10.1093/jac/dkae429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。